Product 15/41

 Previous 
 Return to the Product List 
 Next 

Controversies in Rheumatology

  • ISBN 9780323698283
  • Author: Kay,Schwartzman
  • Publ Date: 2019-07-16
  • Edition:
  • Binding: Hardback

$204.35
Sale: $183.92
Save: 10% off + GST

Add to Cart:
Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.
Whilst every effort is made to keep pricing information up-to-date, prices and availability are subject to change without notice. Where prices or other details have changed from those listed on the website we will contact the customer and only proceed with the order after receiving acceptance of the revised pricing.
Your IP Address is: 3.21.104.183
Copyright © 2024 Medical Books. Powered by Zen Cart